This study is a Swedish historical cohort study in patients prescribed Atacand or Cozaar for hypertension by selected primary care centres. Data will be extracted anonymously from electronic medical records. In addition, data regarding morbidity and mortality will be collected by merging the cohort with the following national registries: the Hospital Discharge Register (Slutenvårdsregistret),...
Date First Received: February 8, 2008
Last Updated: February 8, 2008
Verified by: AstraZeneca, February 2008
Clinical Trial Phase: N/A | Start Date: February 2008
Overall Status: Recruiting
Estimated Enrollment: 5000
Brief Summary
Official Title: “A REtrospective Study on the Effects of cAndesartan vs. Losartan on Blood Pressure, Health Care Consumption and cardiovascuLar Events In a "Real-liFe" GP sEtting in Sweden”
Condition Keyword(s):
Intervention(s):
This study is a Swedish historical cohort study in patients prescribed Atacand or Cozaar for hypertension by selected primary care centres. Data will be extracted anonymously from electronic medical records. In addition, data regarding morbidity and mortality will be collected by merging the cohort with the following national registries: the Hospital Discharge Register (Slutenvårdsregistret), the Cause of Death Register and the Heart Intensive Care Admission (RIKS-HIA)
Study Type: Observational
Study Design: Cohort, Retrospective
Study Primary Completion Date: April 2008
Intervention(s) in this Clinical Trial
- Drug: Candesartan Cilexetil
- oral once daily dose
- Drug: Losartan
- once daily oral dose
Arms, Groups and Cohorts in this Clinical Trial
- : 1
- Candesartan
- : 2
- Losartan
Outcome Measures for this Clinical Trial
Primary Measures
- Blood pressure recordings will be followed for the available observation periods with detail to when and to what degree levels less than 140/90 are reached.
- Time Frame: 1999 - 2007
Safety Issue?: No
- Time Frame: 1999 - 2007
Secondary Measures
- Cardiovascular disease states and procedures in the background and over the entire observation period will be identified by use of ICD-9 and ICD-10 coding for diseases of the cardiovascular system. Specifically are death, acute cardiovascular events, new
- Time Frame: 1999 - 2007
Safety Issue?: No
- Time Frame: 1999 - 2007
- Health care consumption will be assessed as contacts with health care providers, in-hospital time periods for cardiovascular disease states with associated therapeutic procedures, and times spent within various levels of care (e.g. ICU and general ward).
- Time Frame: 1999 - 2007
Safety Issue?: No
- Time Frame: 1999 - 2007
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- Recorded blood pressure prior to therapy of > 140 and/or 90 mmHg
- Diagnosed as hypertensive within 15 months
Exclusion Criteria:
- Previous prescription within 15 months any drug from the ATC groups C02, C03, C07 -
- C09 inclusive
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 17 Years
Maximum Age for this Clinical Trial: N/A
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Sponsor Information
Lead Sponsor: AstraZeneca
Overall Clinical Trial Officials and Contacts
Jan Stålhammar, MD Principal Investigator Eriksbergs vårdcentral
Overall Contact: AstraZeneca Norway Study Information + 47 21 00 64 00 paal.hasvold@astrazeneca.com
Additional Information
Information obtained from ClinicalTrials.gov on August 28, 2008
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00620178
Study ID Number: NIS-CSE-ATA-2008/1
ClinicalTrials.gov Identifier: NCT00620178
Health Authority: Sweden: Regional Ethical Review Board
Clinical Trials Authorship and Review
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.